ORCID as entered in ROS

Select Publications
2024, 'Trends in the use of sodium-glucose cotransporter 2 inhibitors following hospitalisation with heart failure, New South Wales, Australia', presented at 13th Health Services Research Conference, Brisbane, Australia, 05 December 2024 - 06 December 2024
,2024, 'Impact of coordinated care on adherence to antihypertensive medicines among adults experiencing polypharmacy in Australia', presented at 13th Health Services Research Conference, Brisbane, Australia, 04 December 2024 - 06 December 2024
,2024, 'Impact of coordinated care on adherence to antihypertensive medicines among adults experiencing polypharmacy in Australia', presented at 16th Asian Conference on Pharmacoepidemiology, Tokyo, Japan, 12 October 2024 - 14 October 2024
,2024, 'Trends in the use of sodium-glucose cotransporter 2 inhibitors following hospitalisation with heart failure, New South Wales, Australia', presented at 16th Asian Conference on Pharmacoepidemiology, Tokyo, Japan, 12 October 2024 - 14 October 2024
,2023, 'Adherence and persistence to cardiovascular medicines in Australia among people initiating therapy in 2018', in Adherence and persistence to cardiovascular medicines in Australia among people initiating therapy in 2018, presented at 39th International Conference on Pharmacoepidemiology & Therapeutic Risk Management 2023
,2023, 'Trends in the use of Cardiometabolic Medicines in Australia (2014-2022): Sodium-glucose Co-transporter 2 Inhibitors and Glucagon-like Peptide-1 Analogues', in Trends in the use of Cardiometabolic Medicines in Australia (2014-2022): Sodium-glucose Co-transporter 2 Inhibitors and Glucagon-like Peptide-1 Analogues, presented at Australian Diabetes Congress 2023
,2023, 'Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 analogues (GLP-1a) for cardiovascular risk in Australia (2014-2022)', in Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 analogues (GLP-1a) for cardiovascular risk in Australia (2014-2022), presented at 39th International Conference on Pharmacoepidemiology & Therapeutic Risk Management 2023
,2021, 'Herpes zoster vaccine coverage in Australia following a national vaccination program', in Public Health Association of Australia, presented at 17th National Immunisation Conference 2021
,2018, 'Comparison in the associations of office and ambulatory blood pressures with urinary microalbuminuria in community residents with hypertension', in Journal of Hypertension, Lippincott, Williams & Wilkins, Vol. 36, pp. e344 - e344, presented at 27th Scientific Meeting of the International Society of Hypertension, http://dx.doi.org/10.1097/01.hjh.0000549405.61251.8f
,2018, 'Utility of home blood pressure telemonitoring to evaluate early impaired renal function in rural community hypertensive residents: based on dose-response relationship in a cross-sectional study', in Journal of Hypertension, Lippincott, Williams & Wilkins, Vol. 36, pp. e344 - e344, presented at 27th Scientific Meeting of the International Society of Hypertension, http://dx.doi.org/10.1097/01.hjh.0000549406.12832.17
,2025, MyMedicare promises better health care. But only 1 in 10 patients has signed up, InSight+, https://insightplus.mja.com.au/2025/15/mymedicare-promises-better-health-care-but-only-1-in-10-patients-has-signed-up/
,2025, MyMedicare promises better health care. But only 1 in 10 patients has signed up, The Conversation, https://theconversation.com/mymedicare-promises-better-health-care-but-only-1-in-10-patients-has-signed-up-253335
,2021, Impact of a National Immunisation Program on herpes zoster incidence in Australia, http://dx.doi.org/10.1101/2021.08.09.21261775
,2020, Prevalence and molecular epidemiology of methicillin-resistant Staphylococcus aureus colonization with and without methicillin-resistant coagulase-negative Staphylococci in HIV-infected patients, http://dx.doi.org/10.21203/rs.3.rs-17504/v1
,2020, Prevalence, risk factors, phenotypic and molecular characteristics for Staphylococcus aureus carriage in community-based drug users in Guangzhou, China, http://dx.doi.org/10.21203/rs.2.18439/v2
,2019, Prevalence, risk factors, phenotypic and molecular characteristics for Staphylococcus aureus carriage in community-based drug users in Guangzhou, China, http://dx.doi.org/10.21203/rs.2.18439/v1
,2019, Prevalence, risk factors, phenotypic and molecular characteristics for methicillin-resistant Staphylococcus aureus carriage in community-based drug users in Guangzhou, China, http://dx.doi.org/10.21203/rs.2.17914/v1
,2019, School environmental contamination of methicillin-sensitive Staphylococcus aureus as an independent risk factor for nasal colonization in schoolchildren: an observational, cross-sectional study protocol v2, http://dx.doi.org/10.17504/protocols.io.wqvfdw6
,